CLODRONATE DISODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	CH2Cl2O6P2.2Na.4H2O
Molecular Weight	360.917
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.O.[Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O

InChI

InChIKey=XWHPUCFOTRBMGS-UHFFFAOYSA-L

InChI=1S/CH4Cl2O6P2.2Na.4H2O/c2-1(3,10(4,5)6)11(7,8)9;;;;;;/h(H2,4,5,6)(H2,7,8,9);;;4*1H2/q;2*+1;;;;/p-2

HIDE SMILES / InChI

Description
Sources: https://www.medicines.org.uk/emc/medicine/311 |

Clodronate (also known as clodronic acid) is a drug used to treat a high level of calcium in the blood caused by changes in the body that happen with cancer. Clodronate is approved in some countries and is sold under trade trade name bonefos for oral use. Bonefos is indicated in the management of osteolytic lesions, hypercalcemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos is also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcemia of malignancy initially treated with an intravenous bisphosphonate. Bonefos forms complexes with divalent metal ions, and therefore simultaneous administration with food, antacids and mineral supplements may impair absorption. It was suggested, that the mechanism of action of clodronate was involved osteoclast apoptosis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
ADP/ATP translocase 2 3 Target ID: P05141 Gene ID: 292.0 Gene Symbol: SLC25A5 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11961144	Inhibitor 8297
ADP/ATP translocase 3 3 Target ID: P12236 Gene ID: 293.0 Gene Symbol: SLC25A6 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11961144	Inhibitor 8297
ADP/ATP translocase 1 3 Target ID: P12235 Gene ID: 291.0 Gene Symbol: SLC25A4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11961144	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 434 Sources: https://www.medicines.org.uk/emc/medicine/311	Primary		Approved 8429	Bonefos Approved Use Bonefos tablets are indicated in the management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos tablets are also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcaemia of malignancy initially treated with an intravenous bisphosphonate.
Multiple myeloma 159 Sources: https://www.medicines.org.uk/emc/medicine/311	Primary		Approved 8429	Bonefos Approved Use Bonefos tablets are indicated in the management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos tablets are also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcaemia of malignancy initially treated with an intravenous bisphosphonate.

PubMed

Title	Date	PubMed
Strategies for management of prostate cancer-related bone pain.	2001	11888345
Bisphosphonates in multiple myeloma.	2001	11687178
Reduction of visible bone metastases by clodronate therapy in breast cancer.	2001	11501775
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis.	2001	11438040
[Bisphosphonates in the treatment of breast carcinoma].	2001 Aug	11926150
Bisphosphonates in the prevention of bone metastases: current evidence.	2001 Aug	11544581
Dosing regimens and main adverse events of bisphosphonates.	2001 Aug	11544576
A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats.	2001 Aug	11525440
Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible.	2001 Aug	11518354
Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits.	2001 Aug	11508444
Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis--a double blind placebo controlled study.	2001 Dec	11822785
Effects of long-term administration of clodronate on growing rat bone.	2001 Dec	11800232
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.	2001 Dec	11728926
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.	2001 Dec	11720830
[Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].	2001 Jul	11495824
Bisphosphonates may be useful in treatment of bone metastases.	2001 Jul 18	11459865
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma.	2001 Jun	11442499
A method for the selective depletion of perivascular and meningeal macrophages in the central nervous system.	2001 Jun 1	11438173
CD8+ phagocytes in focal ischemia of the rat brain: predominant origin from hematogenous macrophages and targeting to areas of pannecrosis.	2001 May	11484815
The cellular uptake and metabolism of clodronate in RAW 264 macrophages.	2001 Nov	11758762
Suppression of T cells results in long-term survival of mouse heart xenografts in C6-deficient rats.	2001 Nov	11737856
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.	2001 Oct	11762816
Paget's disease of the spine and its management.	2001 Oct	11718191
Meningeal and perivascular macrophages of the central nervous system play a protective role during bacterial meningitis.	2001 Oct 15	11591794
Recent advances in breast cancer (the Twenty-fourth San Antonio Breast Cancer Symposium, December, 2001).	2002	11999142
Treatment of complex regional pain syndrome type I.	2002	11900471
Actions of bisphosphonates in animal models of breast cancer.	2002	11879558
Development of bisphosphonates.	2002	11879557
The present and future role of bisphosphonates in the management of patients with breast cancer.	2002	11879556
Direct effects of bisphosphonates on breast cancer cells.	2002	11879555
Bisphosphonates for breast cancer.	2002	11869664
Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease.	2002 Feb	11870415
Clodronate in myelofibrosis: a case report.	2002 Feb	11863080
Electrospray ionization mass spectrometry and tandem mass spectrometry of clodronate and related bisphosphonate and phosphonate compounds.	2002 Feb	11857764
Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia.	2002 Feb	11841439
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.	2002 Feb 1	11821470
Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.	2002 Jan	11928907
The role of perivascular and meningeal macrophages in experimental allergic encephalomyelitis.	2002 Jan	11777538
Does postmenopausal hormone replacement therapy affect cardiac autonomic regulation in osteoporotic women?	2002 Jan-Feb	11791086
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice.	2002 Jun	12054176
Bisphosphonate prodrugs.	2002 Jun	12052172
Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice.	2002 Jun	12003780
Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines.	2002 Mar	11984068
Disodium chlodronate prevents bone resorption in experimental periodontitis in rats.	2002 Mar	11924589
Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate.	2002 Mar	11874245
[Bisphosphonate therapy in Paget disease?].	2002 Mar 22	11907869
Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis.	2002 May	12027248
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.	2002 May	11961144
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.	2002 May 1	11980672
Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.	2002 May 20	12031126

Patents

Sample Use Guides

In Vivo Use Guide

A daily dose of 1600 mg should be taken as a single dose. When higher daily doses are used, the part of the dose exceeding 1600 mg should be taken separately (as a second dose) as recommended below.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

CLODRONATE DISODIUM

Official Name

English

ZK-00091106

Code

English

BONEFOS

Brand Name

English

CLODRONATE DISODIUM TETRAHYDRATE [EP MONOGRAPH]

Common Name

English

CLODRONATE DISODIUM TETRAHYDRATE [EP IMPURITY]

Common Name

English

CLODRONATE DISODIUM [USAN]

Common Name

English

177501

Code

English

PHOSPHONIC ACID, (DICHLOROMETHYLENE)BIS-, DISODIUM SALT, TETRAHYDRATE

Common Name

English

ZK 00091106

Code

English

CLODRONIC ACID DISODIUM SALT TETRAHYDRATE

Common Name

English

SODIUM CLODRONATE HYDRATE [JAN]

Common Name

English

DISODIUM CLODRONATE

Common Name

English

CLODRONIC ACID DISODIUM SALT [MI]

Common Name

English

CLODRONIC ACID DISODIUM TETRAHYDRATE

Common Name

English

CLODRONATE DISODIUM TETRAHYDRATE

Common Name

English

SODIUM CLODRONATE HYDRATE

Common Name

English

(Dichloromethylene)bisphosphonate disodium tetrahydrate

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

72292